 |
4 Products |  |
1 Disease | | 4 Products |
|
525 Trials |  |
2161 News |  |
| «12...26272829303132333435363738 |
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (clinicaltrials.gov) - Nov 16, 2015
P1/2, N=63, Recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> May 2017
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase classification, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 30, 2015
P2/3, N=110, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> May 2017 Phase classification: P2 --> P2/3
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, P1 data, Trial primary completion date: ALTN: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Oct 28, 2015
P1, N=35, Completed, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Phase classification: P2 --> P2/3 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2015
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) (clinicaltrials.gov) - Oct 26, 2015
P2/3, N=120, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) (clinicaltrials.gov) - Oct 26, 2015
P2/3, N=90, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2015
P2, N=110, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Aug 2016
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Metastases: Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy (clinicaltrials.gov) - Oct 23, 2015
P2, N=60, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Metastases: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0302? (clinicaltrials.gov) - Oct 23, 2015
P2, N=117, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=48, Not yet recruiting, Sponsor: Advenchen Laboratories, LLC
- |||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) (clinicaltrials.gov) - Oct 22, 2015
P2/3, N=378, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=63, Not yet recruiting, Sponsor: Advenchen Laboratories, LLC
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Metastases: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0302? (clinicaltrials.gov) - Aug 11, 2015
P2, N=117, Completed, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) (clinicaltrials.gov) - Jun 3, 2015
P2/3, N=378, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) (clinicaltrials.gov) - May 20, 2015
P2/3, N=318, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Ximotini (simotinib) / Simcere, Advenchen
Trial primary completion date, Metastases: Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC (clinicaltrials.gov) - Apr 14, 2015
P1, N=30, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Dec 2015
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Metastases: Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0303? (clinicaltrials.gov) - Mar 17, 2015
P2/3, N=450, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, P2 data, Metastases: Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） (clinicaltrials.gov) - Feb 19, 2015
P2, N=180, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Oct 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Metastases: Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (clinicaltrials.gov) - Jan 6, 2015
P2/3, N=450, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Metastases: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0302? (clinicaltrials.gov) - Nov 19, 2014
P2, N=110, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 28, 2014
P2, N=110, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: A Phase II Study of Anlotinib in STS Patients (clinicaltrials.gov) - Oct 28, 2014
P2, N=200, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: ALTN: A Phase II Study of Anlotinib in MTC Patients (clinicaltrials.gov) - Oct 28, 2014
P2, N=47, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, P1 data, Trial primary completion date: ALTN: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Oct 28, 2014
P1, N=38, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Nov 2014
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, P2 data, Metastases: Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） (clinicaltrials.gov) - Feb 24, 2014
P2, N=180, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy (clinicaltrials.gov) - Feb 24, 2014
P2, N=60, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 5, 2014
P2, N=110, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0302? (clinicaltrials.gov) - Aug 14, 2013
P2, N=110, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: A Phase II Study of Anlotinib in STS Patients (clinicaltrials.gov) - Jun 13, 2013
P2, N=200, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTN: A Phase II Study of Anlotinib in MTC Patients (clinicaltrials.gov) - Jun 9, 2013
P2, N=47, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, P1 data: ALTN: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Apr 15, 2013
P1, N=38, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||| Ximotini (simotinib) / Simcere, Advenchen
Trial completion: Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects (clinicaltrials.gov) - Jul 8, 2012
P1, N=63, Completed, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Nov 2014 Recruiting --> Completed
- ||| Ximotini (simotinib) / Simcere, Advenchen
New P1 trial: Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects (clinicaltrials.gov) - Nov 8, 2011
P1, N=63, Completed, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.